Titanocene dichloride is the most widely studied red colored solid organometallic compound as a cytotoxic anticancer agent, which means that it can selectively kill cancer cells, and can be used in clinical trials. Cancer refers to any one of a large number of diseases characterized by the development of abnormal cells that divide uncontrollably and spread to the other parts of the body. The anticancer activity shown by titanocene dichloride is expected to increase its demand around the world due to the increasing prevalence of cancer.
For example, cancer is a major public health problem worldwide and is the second leading cause of death in the United States. According to the American Cancer Society, in 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States. Titanocene dichloride has been touted as a potential anti-cancer drug since the late 1970s. After initial clinical trials with this compound against breast and renal-cell cancer, the search for improved derivatives began.
Titanocene dichloride was also studied in phase I clinical trials in 1993 and later in phase II clinical trials and became very important in the field of antitumor drugs. The goal of a primary treatment is to completely remove the cancer from the body or kill all the cancer cells. Any treatment can be used as a primary treatment, but surgery is the most common cancer treatment. Titanium-based therapies have emerged as a promising alternative for the treatment of cancer patients, particularly those with cisplatin resistant tumors.
Moreover, the demand for titanocene dichloride is expected increase due to its varied properties such as electrical conductivity, catalyzing activity in organic-inorganic chemical synthesis, and ability to be incorporated in plant growth hormones, among others. Owing to these properties, titanocene dichloride find a wide variety of applications in various end-use industries, such as electronics, chemicals, and agricultural, among others.
0 Comments